



Palliative Breast Cancer Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for breast cancer used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Regimens highlighted in blue contain an expensive drug that is not currently publicly funded but where there is a universal compassionate access program in place. The administration of the drug supported by the systemic treatment funding model, but not the cost of drug.

Breast Cancer	
Regimen Code	Regimen Abstract
AC	DOXOrubicin 60 mg/m ² IV day 1; Cyclophosphamide 600 mg/m ² IV day 1. Q21 days
ANAS	Anastrozole 1 mg PO daily
CAPE	Capecitabine 1000-1250 mg/m ² PO BID days 1-14. Q21 days <i>Alternative Schedule:</i> Capecitabine 1000-1250 mg/m ² PO BID days 1 – 7. Q14 days
CAPE+TRAS	Capecitabine PO 1000-1250 mg/m ² BID days 1-14; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days
CAPEDOCE	Capecitabine 1000 mg/m ² PO BID, days 1-14; DOCEtaxel 75 mg/m ² IV day 1. Q21 days
CAPELAPA	Capecitabine 1000 mg/m ² PO BID days 1-14; Lapatinib 1250 mg PO daily. Q21 days
CAV	Cyclophosphamide 1000 mg/m ² IV day 1; DOXOrubicin 50 mg/m ² IV day 1; vinCRISTine 1.4 mg/m ² IV day 1. Q21 days <i>For Small Cell Carcinoma</i>

Breast Cancer

Regimen Code	Regimen Abstract
CISP(RT-W)	CISplatin 25-30 mg/m ² IV day 1. Q7 days Concurrent with radiotherapy
CISPETOP(3D)	CISplatin 25 mg/m ² IV days 1-3; Etoposide 100 mg/m ² IV days 1-3. Q21 days <i>For Small Cell Carcinoma</i>
CISPETOP(5D)	CISplatin 20 mg/m ² IV days 1-5; Etoposide 100 mg/m ² IV days 1-5. Q21 days <i>For Small Cell Carcinoma</i>
CISPGEMC(W)	CISplatin 30 mg/m ² IV days 1, 8; Gemcitabine 750 mg/m ² IV days 1, 8. Q21 days
CM(PO)	Cyclophosphamide 50 mg PO daily; Methotrexate 2.5 mg PO BID days 1, 2. Q7 days
CMF(PO)	Cyclophosphamide 100 mg/m ² PO days 1-14; Methotrexate 40 mg/m ² IV days 1, 8; Fluorouracil 600 mg/m ² IV days 1, 8. Q28 days
CMF(PO)+TRAS	Cyclophosphamide 100 mg/m ² PO days 1-14; Methotrexate 40 mg/m ² IV days 1, 8; Fluorouracil 600 mg/m ² IV days 1, 8. Q28 days Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days
CRBP	CARBOplatin AUC 6 IV day 1. Q21 days <i>Note: For use in triple negative or BRCA1/2 mutation-associated breast cancers</i>
CRBPETOP(5D)	CARBOplatin AUC 5 IV days, 1. Etoposide 100 mg/m ² IV days 1-5. Q21 days <i>For Small Cell Carcinoma</i>
CRBPGEMC	CARBOplatin AUC 2 IV days 1, 8; Gemcitabine 800 mg/m ² IV days 1, 8. Q21 days
CRBPPACL	CARBOplatin AUC 5-6 IV day 1; PACLitaxel 175 mg/m ² IV day 1. Q21 days
DOCE	DOCEtaxel 100 mg/m ² IV day 1. Q21 days

Breast Cancer

Regimen Code	Regimen Abstract
DOCE(W)	DOCEtaxel 35-40 mg/m ² IV days 1, 8, 15. Q28 days
DOCE+PERT+TRAS	DOCEtaxel 75-100 mg/m ² IV day 1; Pertuzumab 840 mg IV loading dose followed by 420 mg IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>For cycle 1 only, trastuzumab and docetaxel may be given on day 2</i>
DOCE+TRAS	DOCEtaxel 100 mg/m ² IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days
DOCEGEMC	DOCEtaxel 75 mg/m ² IV day 1; Gemcitabine 1000 mg/m ² IV days 1, 8. Q21 days
DOXO	DOXOrubicin 50 to 75 mg/m ² IV day 1. Q21 days
DOXO(W)	DOXOrubicin 10-20 mg/m ² IV days 1, 8, 15. Q21 - 28 days
EPIR	EPIrubicin 60-90 mg/m ² IV day 1. Q21 days
EPIR(W)	EPIrubicin 25 mg/m ² IV days 1, 8, 15. Q28 days
ERIB	eriBULin 1.4 mg/m ² IV days 1, 8. Q21 days
ETOP(PO)	Etoposide 50 mg PO days 1-14. Q21 days <i>Alternative Dose and Schedule:</i> Etoposide 50-100 mg PO days 1-21. Q28 days
EVEREXEM	Everolimus 10 mg PO daily (5 mg may be considered for certain patients); Exemestane 25 mg PO daily
EXEM	Exemestane 25 mg PO daily
FAC	Fluorouracil 500 mg/m ² IV day 1; DOXOrubicin 50 mg/m ² IV day 1; Cyclophosphamide 500 mg/m ² IV day 1. Q21 days
FEC50	Fluorouracil 500 mg/m ² IV day 1; EPIrubicin 50 mg/m ² IV day 1; Cyclophosphamide 500 mg/m ² IV day 1. Q21 days

Breast Cancer

Regimen Code	Regimen Abstract
GEMC	Gemcitabine 1000 mg/m ² IV days 1, 8. Q21 days <i>Alternative Schedule:</i> Gemcitabine 1000 mg/m ² IV day 1, 8, 15. Q28 days
GOSE	Goserelin 3.6 mg SC. Q28 days
KADC	Trastuzumab Emtansine 3.6 mg/kg IV Q21 days
LETR	Letrozole 2.5 mg PO daily
LPRL	Leuprolide 22.5 mg IM Q3 months
MEDR	Medroxyprogesterone 400 mg/day PO in divided doses
MEGE	Megestrol 160 mg PO daily
NPAC	nab-PACLitaxel 260 mg/m ² IV day 1. Q21 days
NPAC(W)	nab-PACLitaxel 100-150 mg/ ² IV weekly days 1, 8, 15. Q28 days
NPAC(W)+PERT+TRAS	nab-PACLitaxel 100-150 mg/2 IV weekly days 1, 8 - Publicly funded under specific conditions, see PDRP (NDFP) eligibility forms Pertuzumab 840 mg IV loading dose followed by 420 mg IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>For cycle 1 only, trastuzumab and nab-paclitaxel may be given on day 2</i>
NPAC(W)+TRAS	nab-PACLitaxel 100 mg/m ² weekly days 1, 8, 15. Q28 days Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>Alternative Trastuzumab schedule:</i> Trastuzumab 4 mg/kg IV loading dose followed by 2 mg/kg IV days 1, 8, 15, 22. Q28 days
NPAC+PERT+TRAS	nab-PACLitaxel 260 mg/m² IV day 1 - Publicly funded under specific conditions, see PDRP (NDFP) eligibility forms Pertuzumab 840 mg IV loading dose followed by 420 mg IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>For cycle 1 only, trastuzumab and nab-paclitaxel may be given on day 2</i>

Breast Cancer

Regimen Code	Regimen Abstract
NPAC+TRAS	nab-PACLitaxel 260 mg/m ² IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days
PACL	PACLitaxel 175 mg/m ² IV day 1. Q21 days
PACL(W)	PACLitaxel 80 mg/m ² IV days 1, 8, 15. Q28 days
PACL(W)+PERT+TRAS	PACLitaxel 80 mg/m ² IV days 1, 8. (can be given on day 2 in cycle 1 only) Pertuzumab 840 mg IV loading dose followed by 420 mg IV day 1. Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>For cycle 1 only, trastuzumab and paclitaxel may be given on day 2</i>
PACL(W)+TRAS	PACLitaxel 80 mg/m ² IV days 1, 8, 15. Q28 days. Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>Alternative Trastuzumab schedule:</i> Trastuzumab 4 mg/kg IV loading dose followed by 2 mg/kg IV days 1, 8, 15, 22. Q28 days
PACL+PERT+TRAS	PACLitaxel 175 mg/m ² IV day 1; Pertuzumab 840 mg IV loading dose followed by 420 mg IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days <i>For cycle 1 only, trastuzumab and paclitaxel may be given on day 2</i>
PACL+TRAS	PACLitaxel 175 mg/m ² IV day 1; Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days
PERT+TRAS	Pertuzumab 420 mg IV day 1. Trastuzumab 6 mg/kg IV. Q21 days PDRP (NDFP) funding is contingent on the patient previously receiving chemotherapy.
PMDR	Pamidronate 90 mg IV day 1. Q28 days
TMXF	Tamoxifen 20 mg PO daily
TRAS	Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV Q21 days PDRP (NDFP) funding is contingent on the patient previously receiving chemotherapy.

Breast Cancer

Regimen Code	Regimen Abstract
VINO	<p>Vinorelbine 25-30 mg/m² IV days 1, 8, 15. Q28 days</p> <p><i>Alternative Schedule:</i> Vinorelbine 25-30 mg/m² days 1, 8. Q21 days</p>
VINO+TRAS	<p>Vinorelbine 25-30 mg/m² IV days 1, 8, 15. Trastuzumab 4 mg/kg IV loading dose followed by 2 mg/kg IV days 1, 8, 15, 22. Q28 days</p> <p><i>Alternative Schedule:</i> Vinorelbine 25-30 mg/m² days 1, 8. Q21 days Trastuzumab 8 mg/kg IV loading dose followed by 6 mg/kg IV. Q21 days</p>
ZOLE	<p>Zoledronic Acid 4 mg IV day 1. Q28 days</p> <p><i>Alternative Schedule:</i> Zoledronic acid 4 mg IV day 1. Q84 days</p>
DENO	Denosumab 120 mg SC – not currently publicly funded for this regimen and intent Q28 days
FLVS	Fulvestrant 500 mg IM on days 1, 15, 29 (loading dose) THEN Fulvestrant 500 mg IM – not currently publicly funded for this regimen and intent Q28 days
FLVSPALB	Fulvestrant 500 mg IM days 1, 15, 29 (loading dose) – not currently publicly funded for this regimen and intent THEN Fulvestrant 500 mg IM day 1; Palbociclib 125 mg PO days 1-21 – not currently publicly funded for this regimen and intent. Q28 days
LETRPALB	Letrozole 2.5 mg PO daily (continuously) – not currently publicly funded for this regimen and intent; Palbociclib 125 mg PO days 1-21 – not currently publicly funded for this regimen and intent. Q28 days
OLAP	Olaparib 300 mg PO bid (tablet formulation) – not currently publicly funded for this regimen and intent.

Breast Cancer

Regimen Code	Regimen Abstract
PGLDX	Pegylated Liposomal Doxorubicin 40-50 mg/m ² IV day 1. Q28 days Not publicly funded. Universal compassionate access program available

Last Updated: November 2017